344 related articles for article (PubMed ID: 34114604)
1. Development of a physiologically relevant and easily scalable LUHMES cell-based model of G2019S LRRK2-driven Parkinson's disease.
Calamini B; Geyer N; Huss-Braun N; Bernhardt A; Harsany V; Rival P; Cindhuchao M; Hoffmann D; Gratzer S
Dis Model Mech; 2021 Jun; 14(6):. PubMed ID: 34114604
[TBL] [Abstract][Full Text] [Related]
2. Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity.
Nguyen APT; Tsika E; Kelly K; Levine N; Chen X; West AB; Boularand S; Barneoud P; Moore DJ
Proc Natl Acad Sci U S A; 2020 Jul; 117(29):17296-17307. PubMed ID: 32631998
[TBL] [Abstract][Full Text] [Related]
3. Selective expression of Parkinson's disease-related Leucine-rich repeat kinase 2 G2019S missense mutation in midbrain dopaminergic neurons impairs dopamine release and dopaminergic gene expression.
Liu G; Sgobio C; Gu X; Sun L; Lin X; Yu J; Parisiadou L; Xie C; Sastry N; Ding J; Lohr KM; Miller GW; Mateo Y; Lovinger DM; Cai H
Hum Mol Genet; 2015 Sep; 24(18):5299-312. PubMed ID: 26123485
[TBL] [Abstract][Full Text] [Related]
4. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
[TBL] [Abstract][Full Text] [Related]
5. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P
Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188
[TBL] [Abstract][Full Text] [Related]
6. (G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD.
Chen CY; Weng YH; Chien KY; Lin KJ; Yeh TH; Cheng YP; Lu CS; Wang HL
Cell Death Differ; 2012 Oct; 19(10):1623-33. PubMed ID: 22539006
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylation of amyloid precursor protein by mutant LRRK2 promotes AICD activity and neurotoxicity in Parkinson's disease.
Chen ZC; Zhang W; Chua LL; Chai C; Li R; Lin L; Cao Z; Angeles DC; Stanton LW; Peng JH; Zhou ZD; Lim KL; Zeng L; Tan EK
Sci Signal; 2017 Jul; 10(488):. PubMed ID: 28720718
[TBL] [Abstract][Full Text] [Related]
8. LRRK2 G2019S and Parkinson's disease: insight from Neuroinflammation.
Yao XY; Guan LN; Chen Q; Ren C
Postgrad Med J; 2023 Dec; 100(1179):4-11. PubMed ID: 37777187
[TBL] [Abstract][Full Text] [Related]
9. Development of inducible leucine-rich repeat kinase 2 (LRRK2) cell lines for therapeutics development in Parkinson's disease.
Huang L; Shimoji M; Wang J; Shah S; Kamila S; Biehl ER; Lim S; Chang A; Maguire-Zeiss KA; Su X; Federoff HJ
Neurotherapeutics; 2013 Oct; 10(4):840-51. PubMed ID: 23963789
[TBL] [Abstract][Full Text] [Related]
10. Neuronal Firing and Glutamatergic Synapses in the Substantia Nigra Pars Reticulata of LRRK2-G2019S Mice.
Sitzia G; Skiteva O; Chergui K
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358985
[TBL] [Abstract][Full Text] [Related]
11. LRRK2 BAC transgenic rats develop progressive, L-DOPA-responsive motor impairment, and deficits in dopamine circuit function.
Sloan M; Alegre-Abarrategui J; Potgieter D; Kaufmann AK; Exley R; Deltheil T; Threlfell S; Connor-Robson N; Brimblecombe K; Wallings R; Cioroch M; Bannerman DM; Bolam JP; Magill PJ; Cragg SJ; Dodson PD; Wade-Martins R
Hum Mol Genet; 2016 Mar; 25(5):951-63. PubMed ID: 26744332
[TBL] [Abstract][Full Text] [Related]
12. In Vitro CRISPR/Cas9-Directed Gene Editing to Model LRRK2 G2019S Parkinson's Disease in Common Marmosets.
Vermilyea SC; Babinski A; Tran N; To S; Guthrie S; Kluss JH; Schmidt JK; Wiepz GJ; Meyer MG; Murphy ME; Cookson MR; Emborg ME; Golos TG
Sci Rep; 2020 Feb; 10(1):3447. PubMed ID: 32103062
[TBL] [Abstract][Full Text] [Related]
13. Dietary Amino Acids Impact LRRK2-Induced Neurodegeneration in Parkinson's Disease Models.
Chittoor-Vinod VG; Villalobos-Cantor S; Roshak H; Shea K; Abalde-Atristain L; Martin I
J Neurosci; 2020 Aug; 40(32):6234-6249. PubMed ID: 32605938
[TBL] [Abstract][Full Text] [Related]
14. LRRK2-G2019S mice display alterations in glutamatergic synaptic transmission in midbrain dopamine neurons.
Skiteva O; Yao N; Sitzia G; Chergui K
J Neurochem; 2022 Apr; 161(2):158-172. PubMed ID: 35152441
[TBL] [Abstract][Full Text] [Related]
15. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
Ho DH; Seol W; Son I
Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480
[TBL] [Abstract][Full Text] [Related]
16. Analysis of macroautophagy related proteins in G2019S LRRK2 Parkinson's disease brains with Lewy body pathology.
Mamais A; Manzoni C; Nazish I; Arber C; Sonustun B; Wray S; Warner TT; Cookson MR; Lewis PA; Bandopadhyay R
Brain Res; 2018 Dec; 1701():75-84. PubMed ID: 30055128
[TBL] [Abstract][Full Text] [Related]
17. Parkinson's disease-related Leucine-rich repeat kinase 2 modulates nuclear morphology and genomic stability in striatal projection neurons during aging.
Chen X; Xie C; Tian W; Sun L; Zheng W; Hawes S; Chang L; Kung J; Ding J; Chen S; Le W; Cai H
Mol Neurodegener; 2020 Feb; 15(1):12. PubMed ID: 32075681
[TBL] [Abstract][Full Text] [Related]
18. The APP intracellular domain promotes
Zhang ZW; Tu H; Jiang M; Vanan S; Chia SY; Jang SE; Saw WT; Ong ZW; Ma DR; Zhou ZD; Xu J; Guo KH; Yu WP; Ling SC; Margolin RA; Chain DG; Zeng L; Tan EK
Sci Signal; 2022 Aug; 15(748):eabk3411. PubMed ID: 35998231
[TBL] [Abstract][Full Text] [Related]
19. Identification of Targets from LRRK2 Rescue Phenotypes.
Toh J; Chua LL; Ho P; Sandanaraj E; Tang C; Wang H; Tan EK
Cells; 2021 Jan; 10(1):. PubMed ID: 33466414
[TBL] [Abstract][Full Text] [Related]
20. The Relationship between Iron and LRRK2 in a 6-OHDA-Induced Parkinson's Disease Model.
Jia R; Liu Y; Shuai K; Zhou C; Chen L; Zhu L; Wu XM
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
